Scynexis (SCYX) news
Recent news
Scynexis - Phase 2 study of SCY-770 in ADPKD on track to initiate in Q4 2026
AInvest Wire · Oct 6, 2026Scynexis - SCY-770 well tolerated with favorable safety profile at higher doses in phase 1 study
Scynexis recently reported preliminary findings from a Phase 1 clinical trial of its investigational drug SCY-770, indicating that the compound was well tolerated at higher doses with a favorable safety profile. The study, which evaluated the drug’s pharmacokinetics and safety in healthy…
AInvest Wire · Oct 6, 2026Scynexis announces phase 1 study results for SCY-770, a novel, highly selective, oral direct AMPK activator for the treatment of autosomal dominant polycystic kidney disease (ADPKD)
SCYNEXIS, Inc. (NASDAQ: SCYX) has announced the initiation of a Phase 2 clinical trial for SCY-770, a novel, highly selective, oral direct AMPK activator for the treatment of autosomal dominant polycystic kidney disease (ADPKD). The compound was acquired by SCYNEXIS in March 2026 from French…
AInvest Wire · Oct 6, 2026Scynexis appoints seasoned industry veteran Steven K. Burke, M.D., to its board of directors
AInvest Wire · Sep 22, 2026Scynexis appoints Todd Minga, M.D., as senior vice president, research & development
AInvest Wire · Sep 15, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.